<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504309</url>
  </required_header>
  <id_info>
    <org_study_id>G214</org_study_id>
    <nct_id>NCT00504309</nct_id>
  </id_info>
  <brief_title>Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides</brief_title>
  <acronym>OMEGA</acronym>
  <official_title>Omacor: Measures of Endothelial Function and triGlyceride Alteration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of
      an omega-3 fatty acid concentrate in a group of people who normally are not treated for high
      lipids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma/serum samples were analyzed at baseline and at the end of each 8-week treatment period to evaluate the effect of P-OM3 dose on triglycerides, HDL-C, LDL-C, and total cholesterol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow-mediated Dilation (FMD)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on FMD, which is measured as percent change in brachial artery diameter at peak dilation vs. baseline following a 5-minute occlusion period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on heart rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Fatty Acids</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on the percent concentration of select omega-3 fatty acids in red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Inflammatory Markers</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on concentrations of circulating inflammatory markers in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Profile Questionnaires</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on psychosocial questionnaires:
Perceived Stress Scale (PSS)
14 questions, scored 0-4 based on how often the subject felt certain emotions
Scores: 0 to 40; higher scores indicate higher perceived stress
Spielberger State Anxiety Inventory
Levels of state anxiety (situational) and trait anxiety; 40 items scored by a Likert scale
Scores: 20 to 80; higher scores indicate higher levels of anxiety
Positive and Negative Affect Scales (PANAS)
Two 10-item scales; each item is rated on a Likert scale of 1 (not at all) to 5 (very much).
Scores: 10 to 50, with higher scores representing higher levels of positive or negative affect
Center for Epidemiologic Studies Depression (CES-D) Scale
20 questions about symptoms of depression in the past week
Scores: 0 to 60; higher scores indicate more symptomology. Score of 16 or higher indicates a risk for depression and should be followed by further evaluation by a qualified health professional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on the plasma concentration of the inflammatory marker CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of P-OM3 dose on the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI).
HOMA-IR calculates an index of insulin resistance and is calculated as follows: HOMA-IR = (glucose mg/dL * insulin mU/L) / 405.
QUICKI is calculated as follows: QUICKI = 1 / (log(fasting insulin ÂµU/mL) + log(fasting glucose mg/dL)).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>4g P-OM3, then 1g P-OM3, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1g P-OM3, then 4g P-OM3, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then 4g P-OM3, then 1g P-OM3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4g P-OM3, then Placebo, then 1g P-OM3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1g P-OM3, then Placebo, then 4g P-OM3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then 1g P-OM3, then 4g P-OM3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4/day of 4g P-OM3 capsules</intervention_name>
    <description>4/day of 4g P-OM3 capsules for 8 weeks</description>
    <arm_group_label>4g P-OM3, then 1g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>1g P-OM3, then 4g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then 4g P-OM3, then 1g P-OM3</arm_group_label>
    <arm_group_label>4g P-OM3, then Placebo, then 1g P-OM3</arm_group_label>
    <arm_group_label>1g P-OM3, then Placebo, then 4g P-OM3</arm_group_label>
    <arm_group_label>Placebo, then 1g P-OM3, then 4g P-OM3</arm_group_label>
    <other_name>OM3AEE</other_name>
    <other_name>Lovaza</other_name>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4/day of 1g P-OM3 capsules</intervention_name>
    <description>4/day of 1g P-OM3 capsules for 8 weeks</description>
    <arm_group_label>4g P-OM3, then 1g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>1g P-OM3, then 4g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then 4g P-OM3, then 1g P-OM3</arm_group_label>
    <arm_group_label>4g P-OM3, then Placebo, then 1g P-OM3</arm_group_label>
    <arm_group_label>1g P-OM3, then Placebo, then 4g P-OM3</arm_group_label>
    <arm_group_label>Placebo, then 1g P-OM3, then 4g P-OM3</arm_group_label>
    <other_name>OM3AEE</other_name>
    <other_name>Lovaza</other_name>
    <other_name>Fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corn Oil Placebo, 4 capsules/day for 8 weeks</intervention_name>
    <description>4 capsules per day of corn oil placebo for 8 weeks</description>
    <arm_group_label>4g P-OM3, then 1g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>1g P-OM3, then 4g P-OM3, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then 4g P-OM3, then 1g P-OM3</arm_group_label>
    <arm_group_label>4g P-OM3, then Placebo, then 1g P-OM3</arm_group_label>
    <arm_group_label>1g P-OM3, then Placebo, then 4g P-OM3</arm_group_label>
    <arm_group_label>Placebo, then 1g P-OM3, then 4g P-OM3</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  triglycerides 150-500 mg/dL

          -  age 21-65 years

          -  generally healthy

          -  body mass index (BMI) 20-39 kg/m2

        Exclusion Criteria:

          -  smoking

          -  premenopausal (if female)

          -  use of hormone replacement or oral contraceptives

          -  use of lipid lowering or blood pressure medication

          -  hypertension (blood pressure &gt; 150/95 mm Hg)

          -  peripheral vascular disease

          -  heart disease, diabetes, or stroke

          -  inflammatory disease (e.g. rheumatoid arthritis or Crohn's)

          -  elevated liver enzymes

          -  high intake of omega-3 containing foods

          -  allergy to adhesive or latex

          -  use of aspirin, anticoagulants, or SSRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila G West, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann C Skulas-Ray, B.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University General Clinical Research Center</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>June 24, 2011</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Sheila G West</investigator_full_name>
    <investigator_title>Professor of Biobehavioral Health</investigator_title>
  </responsible_party>
  <keyword>triglycerides</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>omega-3</keyword>
  <keyword>n-3</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>EPA</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>DHA</keyword>
  <keyword>flow mediated dilation</keyword>
  <keyword>fish</keyword>
  <keyword>Moderate hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4g P-OM3, Then 1g P-OM3, Then Placebo</title>
          <description>4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks)</description>
        </group>
        <group group_id="P2">
          <title>1g P-OM3, Then 4g P-OM3, Then Placebo</title>
          <description>1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Then 4g P-OM3, Then 1g P-OM3</title>
          <description>Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks</description>
        </group>
        <group group_id="P4">
          <title>4g P-OM3, Then Placebo, Then 1g P-OM3</title>
          <description>4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks</description>
        </group>
        <group group_id="P5">
          <title>1g P-OM3, Then Placebo, Then 4g P-OM3</title>
          <description>1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Then 1g P-OM3, Then 4g P-OM3</title>
          <description>Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1">Participant dropped out during second period</participants>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7">Participant died during washout after 2nd period</participants>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 subject in the &quot;Placebo, 4 g P-OM3, 1 g P-OM3&quot; sequence and 1 subject in the &quot;1 g P-OM3, Placebo, 4 g P-OM3&quot; sequence did not complete the study and were not included in the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>4 g P-OM3, 1 g P-OM3, Placebo</title>
          <description>4 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 1 g/d P-OM3 for 8 weeks, followed by 4 g/d corn oil placebo for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>1 g P-OM3, 4 g P-OM3, Placebo</title>
          <description>1 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 4 g/d P-OM3 for 8 weeks, followed by 4 g/d corn oil placebo for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo, 4 g P-OM3, 1 g P-OM3</title>
          <description>4 g/d corn oil placebo for 8 weeks, followed by 4 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 1 g/d P-OM3 for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>4 g P-OM3, Placebo, 1 g P-OM3</title>
          <description>4 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 4 g/d corn oil placebo for 8 weeks, followed by 1 g/d P-OM3 for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>1 g P-OM3, Placebo, 4 g P-OM3</title>
          <description>1 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 4 g/d corn oil placebo for 8 weeks, followed by 4 g/d P-OM3 for 8 weeks</description>
        </group>
        <group group_id="B6">
          <title>Placebo, 1 g P-OM3, 4 g P-OM3</title>
          <description>4 g/d corn oil placebo for 8 weeks, followed by 1 g/d prescription omega-3 fatty acid ethyl esters (P-OM3) for 8 weeks, followed by 4 g/d P-OM3 for 8 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lipid Profile</title>
        <description>Plasma/serum samples were analyzed at baseline and at the end of each 8-week treatment period to evaluate the effect of P-OM3 dose on triglycerides, HDL-C, LDL-C, and total cholesterol.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile</title>
          <description>Plasma/serum samples were analyzed at baseline and at the end of each 8-week treatment period to evaluate the effect of P-OM3 dose on triglycerides, HDL-C, LDL-C, and total cholesterol.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High density lipoprotein-cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="1.9"/>
                    <measurement group_id="O2" value="42.7" spread="1.9"/>
                    <measurement group_id="O3" value="42.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low density lipoprotein-cholesterol (LDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.3" spread="7.6"/>
                    <measurement group_id="O2" value="127.6" spread="7.6"/>
                    <measurement group_id="O3" value="123.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.9" spread="7.9"/>
                    <measurement group_id="O2" value="212.1" spread="7.9"/>
                    <measurement group_id="O3" value="209" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.7" spread="17.5"/>
                    <measurement group_id="O2" value="215.3" spread="17.5"/>
                    <measurement group_id="O3" value="237.3" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fasting triglycerides (mg/dL) were measured on two consecutive days and averaged for analysis at the end of each treatment period. The null hypothesis was that triglycerides did not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Tukey p-values were used for post hoc comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cholesterol values were compared as the average of two fasting values at the end of each treatment. Cholesterol values included LDL-C, HDL-C, total cholesterol, and calculated ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flow-mediated Dilation (FMD)</title>
        <description>Effect of P-OM3 dose on FMD, which is measured as percent change in brachial artery diameter at peak dilation vs. baseline following a 5-minute occlusion period.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Dilation (FMD)</title>
          <description>Effect of P-OM3 dose on FMD, which is measured as percent change in brachial artery diameter at peak dilation vs. baseline following a 5-minute occlusion period.</description>
          <units>% change in brachial artery diameter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.5"/>
                    <measurement group_id="O2" value="4.03" spread="0.5"/>
                    <measurement group_id="O3" value="5.00" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>Effect of P-OM3 dose on blood pressure</description>
        <time_frame>8 weeks</time_frame>
        <population>Two participants did not complete the study and were therefore excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Corn Oil Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Effect of P-OM3 dose on blood pressure</description>
          <population>Two participants did not complete the study and were therefore excluded from analysis.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure (DBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="1.6"/>
                    <measurement group_id="O2" value="77.7" spread="1.6"/>
                    <measurement group_id="O3" value="77.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure (SBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.3" spread="2.2"/>
                    <measurement group_id="O2" value="129.0" spread="2.2"/>
                    <measurement group_id="O3" value="128.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Effect of P-OM3 dose on heart rate</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Effect of P-OM3 dose on heart rate</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="1.8"/>
                    <measurement group_id="O2" value="69.8" spread="1.8"/>
                    <measurement group_id="O3" value="71.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Fatty Acids</title>
        <description>Effect of P-OM3 dose on the percent concentration of select omega-3 fatty acids in red blood cells</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Fatty Acids</title>
          <description>Effect of P-OM3 dose on the percent concentration of select omega-3 fatty acids in red blood cells</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eicosapentaenoic acid (EPA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.09"/>
                    <measurement group_id="O2" value="1.15" spread="0.09"/>
                    <measurement group_id="O3" value="0.57" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosahexaenoic acid (DHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="0.15"/>
                    <measurement group_id="O2" value="5.34" spread="0.15"/>
                    <measurement group_id="O3" value="4.39" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Omega-3 Index (EPA + DHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.79" spread="0.21"/>
                    <measurement group_id="O2" value="6.49" spread="0.21"/>
                    <measurement group_id="O3" value="4.96" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokine Inflammatory Markers</title>
        <description>Effect of P-OM3 dose on concentrations of circulating inflammatory markers in plasma</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokine Inflammatory Markers</title>
          <description>Effect of P-OM3 dose on concentrations of circulating inflammatory markers in plasma</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleuken-1Î² (IL-1Î²)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.02"/>
                    <measurement group_id="O2" value="0.15" spread="0.02"/>
                    <measurement group_id="O3" value="0.15" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleuken-6 (IL-6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.15"/>
                    <measurement group_id="O2" value="0.85" spread="0.15"/>
                    <measurement group_id="O3" value="0.87" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor-Î± (TNF-Î±)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.07"/>
                    <measurement group_id="O2" value="1.11" spread="0.14"/>
                    <measurement group_id="O3" value="1.20" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <description>Effect of P-OM3 dose on fasting glucose</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>Effect of P-OM3 dose on fasting glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" spread="1.9"/>
                    <measurement group_id="O2" value="98.0" spread="1.9"/>
                    <measurement group_id="O3" value="96.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychosocial Profile Questionnaires</title>
        <description>Effect of P-OM3 dose on psychosocial questionnaires:
Perceived Stress Scale (PSS)
14 questions, scored 0-4 based on how often the subject felt certain emotions
Scores: 0 to 40; higher scores indicate higher perceived stress
Spielberger State Anxiety Inventory
Levels of state anxiety (situational) and trait anxiety; 40 items scored by a Likert scale
Scores: 20 to 80; higher scores indicate higher levels of anxiety
Positive and Negative Affect Scales (PANAS)
Two 10-item scales; each item is rated on a Likert scale of 1 (not at all) to 5 (very much).
Scores: 10 to 50, with higher scores representing higher levels of positive or negative affect
Center for Epidemiologic Studies Depression (CES-D) Scale
20 questions about symptoms of depression in the past week
Scores: 0 to 60; higher scores indicate more symptomology. Score of 16 or higher indicates a risk for depression and should be followed by further evaluation by a qualified health professional</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn Oil Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Psychosocial Profile Questionnaires</title>
          <description>Effect of P-OM3 dose on psychosocial questionnaires:
Perceived Stress Scale (PSS)
14 questions, scored 0-4 based on how often the subject felt certain emotions
Scores: 0 to 40; higher scores indicate higher perceived stress
Spielberger State Anxiety Inventory
Levels of state anxiety (situational) and trait anxiety; 40 items scored by a Likert scale
Scores: 20 to 80; higher scores indicate higher levels of anxiety
Positive and Negative Affect Scales (PANAS)
Two 10-item scales; each item is rated on a Likert scale of 1 (not at all) to 5 (very much).
Scores: 10 to 50, with higher scores representing higher levels of positive or negative affect
Center for Epidemiologic Studies Depression (CES-D) Scale
20 questions about symptoms of depression in the past week
Scores: 0 to 60; higher scores indicate more symptomology. Score of 16 or higher indicates a risk for depression and should be followed by further evaluation by a qualified health professional</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Perceived Stress Scale (PSS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="2.2"/>
                    <measurement group_id="O2" value="23.7" spread="2.4"/>
                    <measurement group_id="O3" value="22.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Scale (PANAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="2.2"/>
                    <measurement group_id="O2" value="35.0" spread="2.4"/>
                    <measurement group_id="O3" value="35.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Scale (PANAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="2.4"/>
                    <measurement group_id="O2" value="13.3" spread="2.5"/>
                    <measurement group_id="O3" value="11.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CES-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.9"/>
                    <measurement group_id="O2" value="3.3" spread="3.1"/>
                    <measurement group_id="O3" value="2.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spielberger State Anxiety Inventory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="1.5"/>
                    <measurement group_id="O2" value="46.5" spread="1.6"/>
                    <measurement group_id="O3" value="45.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (CRP)</title>
        <description>Effect of P-OM3 dose on the plasma concentration of the inflammatory marker CRP</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP)</title>
          <description>Effect of P-OM3 dose on the plasma concentration of the inflammatory marker CRP</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.2"/>
                    <measurement group_id="O2" value="1.32" spread="0.2"/>
                    <measurement group_id="O3" value="1.45" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin</title>
        <description>Effect of P-OM3 dose on fasting insulin</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin</title>
          <description>Effect of P-OM3 dose on fasting insulin</description>
          <units>Î¼IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="1.4"/>
                    <measurement group_id="O2" value="15.5" spread="1.4"/>
                    <measurement group_id="O3" value="14.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>Effect of P-OM3 dose on the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI).
HOMA-IR calculates an index of insulin resistance and is calculated as follows: HOMA-IR = (glucose mg/dL * insulin mU/L) / 405.
QUICKI is calculated as follows: QUICKI = 1 / (log(fasting insulin ÂµU/mL) + log(fasting glucose mg/dL)).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4g P-OM3</title>
            <description>4 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O2">
            <title>1g P-OM3</title>
            <description>1 g/d Prescription Omega-3 acid ethyl esters (P-OM3)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>4 g/d corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>Effect of P-OM3 dose on the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI).
HOMA-IR calculates an index of insulin resistance and is calculated as follows: HOMA-IR = (glucose mg/dL * insulin mU/L) / 405.
QUICKI is calculated as follows: QUICKI = 1 / (log(fasting insulin ÂµU/mL) + log(fasting glucose mg/dL)).</description>
          <units>index units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HOMA-IR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.4"/>
                    <measurement group_id="O2" value="3.75" spread="0.4"/>
                    <measurement group_id="O3" value="3.55" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QUICKI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.002"/>
                    <measurement group_id="O2" value="0.14" spread="0.002"/>
                    <measurement group_id="O3" value="0.14" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected while participants were enrolled (approximately 2.5 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4g P-OM3</title>
          <description>4 g Prescription Omega-3 acid ethyl esters (P-OM3)</description>
        </group>
        <group group_id="E2">
          <title>1g P-OM3</title>
          <description>1 g Prescription Omega-3 acid ethyl esters (P-OM3)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Corn oil placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>Lower GI symptoms that contributed to withdrawal from the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Skulas-Ray</name_or_title>
      <organization>Penn State University</organization>
      <phone>814-863-0856</phone>
      <email>aus164@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

